利巴韦林联合IFN治疗冠状病毒感染的研究进展

Research progress of ribavirin combined with IFN in treatment of coronavirus infection

2019年底以来新型冠状病毒肺炎(新冠肺炎)席卷全球,病毒学分类委员会将新型冠状病毒命名为SARSCoV-2。目前对SARS-CoV-2知之甚少,尚未研发出针对该疾病的特效药物。但其与严重急性呼吸综合征冠状病毒、中东呼吸综合征冠状病毒同为β属冠状病毒,具有核苷酸同源性。既往严重急性呼吸综合征和中东呼吸综合征相关研究提示利巴韦林(ribavirin,RBV)联合IFN抗病毒治疗有效,为新冠肺炎的治疗提供了新的方向,但联合治疗的效果及安全性有待进一步临床试验证实。本文回顾总结了RBV联合IFN治疗冠状病毒感染的研究进展,以期为新冠肺炎的治疗提供参考。

The novel coronavirus pneumonia has swept over the world since the end of 2019.The International Committee on Taxonomy of Viruses has named novel coronavirus as SARS-CoV-2.At present,little is known about SARS-CoV-2,and no specific drug has been developed for the disease.However,they are β-coronaviruses with the same nucleotide origin as severe acute respiratory syndrome coronavirus(SARS-CoV)and Middle East respiratory syndrome coronavirus(MERS-CoV).Previous studies on SARS and MERS suggest that ribavirin(RBV)combined with IFN is an effective antiviral therapy and provide a new direction for the treatment of novel coronavirus pneumonia.However,the efficacy and safety of the combined therapy need to be confirmed in further clinical trials.In this paper,research progress on the RBV+IFN in treatment of CoV infection is reviewed and summarized with expectations to provide reference for treating novel coronavirus pneumonia.